Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IG301
- Development stage
- Preclinical
- Lead developer
- Ingenium Therapeutics
- Modality
- Gene Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
IG301 is a preclinical-stage, in vivo chimeric antigen receptor natural killer (CAR-NK) cell therapy platform being developed by Ingenium Therapeutics in collaboration with Yale University. It utilizes a fusion cytokine-based, fifth-generation CAR-encoding mRNA delivered via a non-lipid nanoparticle (specifically, a polyplex-based "Proteinplex" gene delivery system) to directly reprogram endogenous NK cells in vivo. This approach bypasses the complexities and high costs of ex vivo cell manufacturing, enabling transient CAR expression and targeted cytotoxicity against solid tumors. The delivery system is designed to target specific organs, including the liver, lung, and pancreas, while avoiding systemic immunogenicity.
- Other names
- IGCARin vivo CAR-NK
Beyond the preview
Go deeper on IG301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IG301.